Tanvex BioPharma, Inc. (TPE:6541)

Tanvex BioPharma Revenue

Tanvex BioPharma had revenue of 220.44M TWD in the quarter ending June 30, 2026, with 370.84% growth. This brings the company's total for the last twelve months to 657.56M, up 492.43% year-over-year. In the year 2025, Tanvex BioPharma had annual revenue of 400.97M with 1,056.27% growth. That makes Tanvex BioPharma the 33,759th largest company in the world by revenue and 1,758th in Taiwan.

• Revenue (ttm): 657.56M
• Revenue Growth: +492.43%
• P/S Ratio: 12.53
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 8.24B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• United States 230.94M 57.6%
• Taiwan 170.03M 42.4%

Fiscal year ended Dec 31, 2025 See the full Tanvex BioPharma breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	400.97M	366.29M	1,056.27%
Dec 31, 2024	34.68M	-26.73M	-43.53%
Dec 31, 2023	61.41M	39.01M	174.11%
Dec 31, 2022	22.40M	17.00M	314.43%
Dec 31, 2021	5.41M	5.11M	1,702.00%

Data Source: S&P Global Market Intelligence Last updated: Aug 24, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 18, 2026

Data Sources Report a data error